This reminder follows updates to product information and the National Institute for Health and Care Excellence (NICE) guidance for short-acting beta 2 agonists (SABAs), including salbutamol and ...

Thanks to improved treatments, many people with asthma live good lives. However, for a smaller group—those with severe asthma ...

Symptoms include wheezing, shortness of breath, recurrent cough, and chest tightness. Fear of cortisone remains one of the ...

CLEVELAND, Ohio. (KFSN) -- About 25 million Americans suffer from asthma. For people with severe forms of the disease, every single breath can be a struggle. Now, there's new hope for these patients A ...

Breztri becomes the first single-inhaler triple therapy for patients as young as 12 years ...

Adults with moderate to severe asthma with uncontrolled symptoms had significantly improved asthma control with daily oral ...

The ultra-long acting investigational biologic is administered once every 6 months as a subcutaneous injection. Depemokimab reduced the rate of exacerbations in patients with severe asthma with type 2 ...

SAN ANTONIO — For children, a visit to the emergency department for an asthma attack is a red flag for future acute-care visits, and could be used to identify patients who might benefit from ...

For World Asthma Day, GINA is spotlighting the need for greater access to inhaled corticosteroids for everyone, from adults ...

Connect Biopharma Holdings Limited has announced the initiation of its Phase 2 Seabreeze STAT Asthma study, which aims to evaluate the safety and efficacy of rademikibart in treating acute ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...